The evolution of insulin glargine and its continuing contribution to diabetes care
about
Soluble insulin analogs combining rapid- and long-acting hypoglycemic properties - From an efficient E. coli expression system to a pharmaceutical formulation.U300, a novel long-acting insulin formulation.New Basal Insulins: a Clinical Perspective of Their Use in the Treatment of Type 2 Diabetes and Novel Treatment Options Beyond Basal Insulin.Development of glucose-responsive 'smart' insulin systems.Efficacy and safety of LY2963016 insulin glargine in patients with type 1 and type 2 diabetes previously treated with insulin glargine.Comparison of trajectories of self-monitored glucose levels by hypoglycemia status over 52 weeks of treatment with insulin glargine or exenatide once weekly.Characteristics of insulin-Naïve people with type 2 diabetes who successfully respond to insulin glargine U100 after 24 weeks of treatment: a meta-analysis of individual participant data from 3 randomized clinical trials.A Review of Basal-Bolus Therapy Using Insulin Glargine and Insulin Lispro in the Management of Diabetes Mellitus.A Commentary: effects on glargine insulin on glycemic control in patients with diabetes mellitus type II undergoing off-pump coronary artery bypass graft.
P2860
Q36308899-9282DF25-2C33-4AD8-9614-F0D25FC4556CQ38259756-0D1A7396-81A2-465B-A87C-9344BEB79B56Q38640170-50581BFF-99BF-4E83-B012-1176C3F59AA0Q39309814-DEB2594C-DE90-4197-9662-35A5F7D8773CQ40125071-9424F911-19DF-407E-828F-833F9449BAA6Q41586046-C0D34A52-F31D-46B8-88B7-20914A250B4FQ54975989-9B65CC73-98A4-41C2-9E65-BA10C89C3A04Q55162068-FD63CF70-878D-4A07-B933-613FE0F8EEFCQ55267559-6758A009-41CC-4CB6-85B1-EF83484B7959
P2860
The evolution of insulin glargine and its continuing contribution to diabetes care
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
The evolution of insulin glargine and its continuing contribution to diabetes care
@ast
The evolution of insulin glargine and its continuing contribution to diabetes care
@en
The evolution of insulin glargine and its continuing contribution to diabetes care
@nl
type
label
The evolution of insulin glargine and its continuing contribution to diabetes care
@ast
The evolution of insulin glargine and its continuing contribution to diabetes care
@en
The evolution of insulin glargine and its continuing contribution to diabetes care
@nl
prefLabel
The evolution of insulin glargine and its continuing contribution to diabetes care
@ast
The evolution of insulin glargine and its continuing contribution to diabetes care
@en
The evolution of insulin glargine and its continuing contribution to diabetes care
@nl
P2093
P2860
P921
P1433
P1476
The evolution of insulin glargine and its continuing contribution to diabetes care
@en
P2093
David R. Owens
Gerhard Seipke
Harald Berchtold
P2860
P2888
P304
P356
10.1007/S40265-014-0226-4
P407
P577
2014-06-01T00:00:00Z
P5875
P6179
1027355192